Roth Capital Reinstates Buy on Monopar Therapeutics, Announces $18 Price Target
Roth Capital analyst Kumaraguru Raja reinstates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and announces $18 price target.
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers Baudax Bio (NASDAQ:BXRX) stock moved upwards by 61.2% to $6.56 during Friday’s pre-market session. The company’s market…
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 574 stocks hit new 52-week lows.
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Sean Lee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and lowers the price target from $9 to $6.
Monopar Therapeutics: Q2 Earnings Insights
Monopar Therapeutics (NASDAQ:MNPR) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.